Patient-Derived Gastric Cancer Assembloids: Integrating Tumor Organoids and Stromal Cell Subpopulations for Enhanced Preclinical Modeling

Study Background and Research Question

Gastric cancer remains a leading cause of cancer-related mortality worldwide, with a five-year survival rate below 10% for advanced cases. The poor prognosis is largely attributed to the pronounced heterogeneity of gastric tumors and the resulting variability in treatment response. Traditional three-dimensional (3D) tumor models, including patient-derived organoids, have improved the field but still fall short of recapitulating the full cellular complexity and microenvironmental dynamics of primary tumors. In particular, these models often lack the diverse stromal populations—such as cancer-associated fibroblasts and mesenchymal cells—that influence tumor progression, therapeutic resistance, and clinical outcomes. The reference study (Shapira-Netanelov et al., 2025) addresses this crucial gap by asking: Can integrating autologous stromal subtypes with patient-derived gastric tumor organoids yield a more predictive and physiologically relevant in vitro platform for drug discovery and personalized therapy optimization?

Key Innovation from the Reference Study

The core innovation lies in the development of a patient-derived gastric cancer "assembloid" model. Unlike standard organoid cultures, this assembloid system integrates epithelial tumor organoids with multiple matched stromal subpopulations—including mesenchymal stem cells, fibroblasts, and endothelial cells—all derived from the same patient tumor. This approach enables the recreation of the cellular heterogeneity and microenvironment present in primary gastric tumors. The co-culture design permits researchers to probe not only tumor-intrinsic drug responses but also the influence of stromal-tumor interactions on gene expression profiles, signaling pathways, and resistance mechanisms.

Methods and Experimental Design Insights

The reference study established a multi-step workflow:

• Tumor samples from gastric cancer patients were enzymatically and mechanically dissociated to obtain single-cell suspensions.
• Distinct subpopulations—including epithelial, mesenchymal, fibroblastic, and endothelial cells—were expanded in tailored media optimized for each lineage.
• These cell types were then recombined in a defined co-culture medium to form assembloids. This medium supported the growth and maintenance of all included subpopulations, enabling sustained cell–cell interactions.
• Immunofluorescence staining was used to confirm the presence and spatial arrangement of both epithelial and stromal markers within the assembloids.
• Transcriptomic profiling by RNA sequencing characterized gene expression changes driven by stromal integration.
• Drug response assays (cell viability and proliferation) were performed to assess sensitivity and resistance to various chemotherapeutic and targeted agents.

This modular workflow allows for flexible tailoring of stromal composition, supporting comparative studies across patient samples and therapeutic regimens.

Core Findings and Why They Matter

Several key findings emerged from the study:

• The gastric cancer assembloids recapitulated the cellular heterogeneity and microenvironmental context of primary tumors more effectively than organoid monocultures, as validated by biomarker expression and spatial organization.
• Transcriptomic analyses revealed that assembloids exhibited elevated expression of inflammatory cytokines, extracellular matrix remodeling factors, and tumor progression-related genes—mimicking in vivo tumor–stroma signaling.
• Drug screening demonstrated marked patient- and drug-specific variability in response. Notably, certain agents effective in organoid monoculture lost efficacy in the assembloid context, highlighting the modulating influence of stromal cells on drug sensitivity and resistance (reference).
• This model enables detailed investigation of resistance mechanisms, including those relevant to antifolate drugs, and provides a platform for optimizing combination therapies based on patient-specific biology.

These results underscore the assembloid’s value as a bridge between simplistic in vitro systems and the complexity of human tumors, with direct implications for personalized medicine and preclinical drug testing.

Comparison with Existing Internal Articles

Recent internal literature provides complementary perspectives on the integration of folate analogs, such as Leucovorin Calcium, into advanced cancer models. For instance, "Leucovorin Calcium in Translational Cancer Research: Bridging Antifolate Resistance and Tumor Heterogeneity" discusses how calcium folinate is enabling translational scientists to model methotrexate rescue and antifolate drug resistance within physiologically relevant microenvironments, including assembloid platforms. The article "Leucovorin Calcium: Strategic Integration of a Folate Analog" further contextualizes the mechanistic and translational utility of Leucovorin Calcium in overcoming methotrexate-induced growth suppression and enhancing preclinical rigor in multi-cellular tumor models. Both articles highlight the strategic necessity of incorporating high-purity folate analogs into workflows that seek to model true tumor–stroma crosstalk and to interpret drug response variability—an approach now validated by the reference assembloid study.

Limitations and Transferability

While the gastric cancer assembloid model represents a major advance, it is important to note several limitations:

• The technical complexity and resource intensity of isolating and expanding multiple autologous cell types may limit throughput and cross-lab reproducibility.
• Although the model recapitulates cellular heterogeneity and some aspects of the tumor microenvironment, it may not fully capture the immune landscape or vascularization present in vivo.
• Drug response assays in assembloid systems require careful calibration of cell proliferation and viability endpoints, especially when comparing to monoculture controls.
• The transferability of this platform to other cancer types or broader clinical settings will depend on further standardization and validation efforts.

Nevertheless, the model provides a tractable system for dissecting complex cell–cell interactions and informing precision therapeutic strategies.

Protocol Parameters

• Tumor dissociation: Use enzymatic and mechanical methods to generate single-cell suspensions from fresh gastric tumor tissue.
• Stromal subpopulation expansion: Culture isolated cells in lineage-specific media (e.g., mesenchymal, fibroblast, endothelial) for 7–14 days prior to assembloid formation.
• Assembloid co-culture: Combine organoid and stromal cell suspensions in a defined ratio (as optimized in the reference study) within an assembloid-supportive medium; culture for at least 5–7 days before downstream analysis.
• Drug screening: Apply test compounds for 72 hours, then assess cell viability and proliferation using appropriate assays tailored to mixed-cell populations.
• Folate rescue experiments: When modeling protection from methotrexate-induced growth suppression, pre-treat assembloids with Leucovorin Calcium (e.g., 10–100 μM, as established in cell-based assays) and monitor cell proliferation endpoints.
• Sample storage and handling: For folate analogs such as Leucovorin Calcium, dissolve at ≥15.04 mg/mL in water with gentle warming, and store aliquots at -20°C; use solutions promptly to preserve activity (product information).

Research Support Resources

Researchers aiming to model tumor–stroma interactions, antifolate drug resistance, or methotrexate rescue in assembloid systems can leverage high-quality reagents to ensure experimental reproducibility. Leucovorin Calcium (SKU A2489) from APExBIO is a water-soluble, high-purity folate analog designed for scientific research, offering reliable protection from methotrexate-induced growth suppression and supporting rigorous cell proliferation assays. Adhering to best-practice protocols—including correct storage at -20°C and prompt use of prepared solutions—will help maintain assay consistency in advanced gastric cancer assembloid workflows.